Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Tao OUYANG
- Target Recruit Count
- 54
- Registration Number
- NCT01589159
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Beijing, China
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 128
- Registration Number
- NCT01588990
- Locations
- 🇦🇺
Calvary North Adelaide; North Adeliade Oncology Centre, North Adelaide, South Australia, Australia
🇦🇺Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01584544
- Locations
- 🇨🇳
radiation department, Cancer Hospital, CAMS, Beijing, Beijing, China
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
- First Posted Date
- 2012-04-09
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 580
- Registration Number
- NCT01573468
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 37
- Registration Number
- NCT01558869
- Locations
- 🇭🇰
Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong
Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma
- Conditions
- Colorectal Adenocarcinoma
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT01552967
- Locations
- 🇨🇳
the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy
- Conditions
- Hilar CholangiocarcinomaPrimary Sclerosing Cholangitis
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- Azienda Ospedaliera di Padova
- Target Recruit Count
- 33
- Registration Number
- NCT01549795
- Locations
- 🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
- Conditions
- Extrahepatic Bile Duct CancerNauseaVomitingStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
- Interventions
- Drug: aprepitantDrug: gemcitabine hydrochlorideDrug: capecitabineDrug: fluorouracilProcedure: radiation therapyOther: questionnaire administrationProcedure: quality-of-life assessmentProcedure: nausea and vomiting therapyProcedure: management of therapy complications
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 22
- Registration Number
- NCT01534637
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Second Line Therapy in Advanced Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 52
- Registration Number
- NCT01530503
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi, Bologna, Italy
🇮🇹A.O. Ospedali Riuniti, Bergamo, Italy
🇮🇹Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G Salesi, Ancona, Italy
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
- Conditions
- GastrinomaPancreatic Polypeptide TumorRecurrent Islet Cell CarcinomaGlucagonomaInsulinomaRecurrent Pancreatic CancerSomatostatinomaStage IV Pancreatic CancerStage III Pancreatic Cancer
- Interventions
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Shaheen Shagufta
- Target Recruit Count
- 20
- Registration Number
- NCT01525082
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.